AnaptysBio (ANAB) AI Stock Analysis

• Market Cap: $1.10B
• Dividend Yield: N/A
• Average Volume (3M): 537.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: 196.42%
• EPS Growth: 53.92%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.52
• Shares Outstanding: 27,688,470
• 10 Day Avg. Volume: 885,334
• 30 Day Avg. Volume: 537,307
• PEG Ratio: 0.16
• Price to Book (P/B): 5.30
• Price to Sales (P/S): 4.12
• P/FCF Ratio: -2.77
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 5.82
• Enterprise Value/Gross Profit: 59.88
• Enterprise Value/Ebitda: -215.76
• 1Y Price Target: $66.50
• Price Target Upside: 67.89% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -1.69
• Revenue Forecast (FY): $204.72M

• Rating: 51 Neutral
• Price Target: $37.00 ▼(-6.59% Downside)

AnaptysBio's overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and a precarious balance sheet. While technical indicators show positive momentum, the negative valuation metrics due to ongoing losses further weigh down the score.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong performance and potential for future expansion, enhancing long-term business viability.

Pipeline Strength

Strong clinical trial results for pipeline candidates like rosnilimab suggest promising future product offerings and competitive positioning.

Strategic Asset Separation

Separating assets could unlock value by allowing focused development and investment, enhancing strategic clarity and investor appeal.

Negative Factors

Profitability Challenges

Persistent profitability issues indicate operational inefficiencies, which may hinder long-term financial stability and growth potential.

Weak Balance Sheet

A precarious balance sheet with negative equity suggests potential solvency risks, impacting financial health and strategic flexibility.

Cash Flow Issues

Negative operating cash flow reflects ongoing cash burn, which could limit the company's ability to fund operations and invest in growth.

AnaptysBio Business Overview & Revenue Model

Company Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

How the Company Makes Money

AnaptysBio generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies. The company enters into strategic alliances that often involve upfront payments, milestone payments contingent on the achievement of specific development goals, and royalties on future product sales. Additionally, AnaptysBio may receive funding for research and development activities as part of these collaborations. This model allows the company to monetize its innovative antibody platform and pipeline candidates while sharing the financial risks associated with drug development. As of now, the company has not yet commercialized any products, so its revenue is largely dependent on these partnerships and potential future royalties.

AnaptysBio Financial Statement Overview

Summary

AnaptysBio faces significant financial challenges, with persistent losses and a weak balance sheet. The income statement shows a negative net profit margin and declining gross profit margin. The balance sheet reveals negative stockholders' equity and poor returns for shareholders. Cash flow analysis indicates cash burn despite some improvement in free cash flow growth.

Income Statement

AnaptysBio's income statement shows significant challenges with profitability. The company has a negative net profit margin of -49.94% in the TTM, indicating substantial losses relative to revenue. Despite a strong revenue growth rate of 37.60% in the TTM, the EBIT and EBITDA margins remain negative, reflecting ongoing operational inefficiencies. The gross profit margin has decreased from 97.37% in 2024 to 54.61% in the TTM, suggesting increased cost pressures.

Balance Sheet

The balance sheet reveals a precarious financial position with negative stockholders' equity in the TTM, resulting in an undefined debt-to-equity ratio. This indicates potential solvency issues. The return on equity is significantly negative at -1101.24%, highlighting poor returns for shareholders. The equity ratio is also negative, reflecting a concerning capital structure.

Cash Flow

Cash flow analysis shows improvement in free cash flow growth at 13.46% in the TTM, but the operating cash flow remains negative, indicating cash burn. The operating cash flow to net income ratio is -3.80, suggesting that cash outflows are not being adequately covered by income. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is slightly better aligned with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	169.47M	91.28M	17.16M	10.29M	63.17M	75.00M
Gross Profit	16.47M	-72.56M	-115.13M	-78.51M	-35.32M	-5.03M
EBITDA	-4.57M	-92.74M	-156.42M	-105.26M	-55.71M	-19.37M
Net Income	-84.63M	-145.23M	-163.62M	-128.72M	-57.80M	-19.93M
Balance Sheet
Total Assets	353.10M	483.83M	452.39M	610.38M	643.07M	416.55M
Cash, Cash Equivalents and Short-Term Investments	248.96M	385.37M	390.90M	441.24M	548.10M	393.65M
Total Debt	346.45M	369.46M	17.81M	19.45M	20.95M	342.00K
Total Liabilities	382.51M	412.97M	364.29M	348.28M	286.64M	19.82M
Stockholders Equity	-29.42M	70.87M	88.10M	262.10M	356.43M	396.73M
Cash Flow
Free Cash Flow	-145.32M	-135.69M	-121.61M	-73.95M	-47.29M	-14.73M
Operating Cash Flow	-144.97M	-135.34M	-120.80M	-73.59M	-45.92M	-14.16M
Investing Cash Flow	125.14M	95.40M	144.75M	-394.85M	38.84M	94.47M
Financing Cash Flow	-61.91M	127.05M	-59.30M	44.02M	252.30M	-879.00K

AnaptysBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 39.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 39.61 is above the 20-day moving average (MA) of 35.77, above the 50-day MA of 31.16, and above the 200-day MA of 23.35, indicating a bullish trend. The MACD of 1.18 indicates Positive momentum. The RSI at 62.28 is Neutral, neither overbought nor oversold. The STOCH value of 72.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.

AnaptysBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	73 Outperform	$513.66M	10.90	10.43%	―	37798.31%	―
CMPX	60 Neutral	$866.19M	―	-37.82%	―	-100.00%	-28.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANAB	51 Neutral	$1.10B	―	-308.02%	―	196.42%	53.92%
OLMA	46 Neutral	$1.33B	―	-59.22%	―	―	17.23%
TERN	45 Neutral	$2.44B	―	-29.12%	―	―	12.45%
MGTX	44 Neutral	$610.12M	―	-611.42%	―	96.83%	-61.92%

AnaptysBio Corporate Events

AnaptysBio Reports Q3 2025 Results and Strategic Plans

AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in the development of innovative immunology therapeutics for autoimmune and inflammatory diseases, with a focus on pioneering treatments like rosnilimab and ANB033.

AnaptysBio Announces Business Separation Plans

On September 29, 2025, AnaptysBio announced plans to separate its business into two independent, publicly traded companies by the end of 2026. This strategic move aims to maximize shareholder value by allowing investors to align with each company’s distinct strategic and financial objectives. The separation will create a Royalty Management Company to manage substantial royalties and a Biopharma Company focused on developing and commercializing therapeutics. This decision reflects AnaptysBio’s commitment to unlocking and maximizing value for its stakeholders.

The most recent analyst rating on (ANAB) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.